Hydrolyzed Oyster Extract for Liver Health: a Randomized, Double-blind, Placebo-controlled Trial
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 96
- 主要终点
- Change of serum alanine aminotransferase (ALT)
研究概览
简要总结
This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal. A total of 96 participants will be randomly allocated to active (oyster) or placebo group (1:1). Each group will receive 750 mg of oyster extract or placebo per day for 8 weeks. Primary outcome will be the change in ALT level and secondary outcomes will be; (1) ratios of participants with normal ALT, aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT); (2) the change in serum bilirubin; (3) the change in multi-dimensional fatigue inventory; (4) the changes in serum lipids; (5) the changes in antioxidant enzymes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age over 19
- •AST, ALT, and GGT levels above the upper limit of the normal but less than 3 times the upper limit of the normal
- •Participants with normal physical activity who sign an informed consent form
- •Fatty liver detected by ultrasound
排除标准
- •Allergic reaction to oyster
- •Uncontrolled diabetes mellitus
- •Active viral hepatitis and any liver diseases that can affect trial outcomes (positive for HBs Ag or HCV Ab)
- •Liver cirrhosis of Child-Pugh class B or C
- •Chemotherapy or radiation therapy for cancer within 6 months
- •Cholelithiasis
- •Systemic medications that can affect liver function such as INH, valproic acid, tetracycline, allopurinol, phenytoin, phenelzine, sertraline, naproxen and diclofenac within 4 weeks
- •Medication of cholagogues, cholelitholytics & hepatic protectors, antidotes, detoxifying agents, and drug abuse (drugs used in substance dependence) within 4 weeks
- •Alcoholism or excessive alcohol intake of more than 168 g/week in men and 112 g/week in women
- •Kidney diseases or serum creatinine level above 2.0 mg/dL
- •Uncontrolled hypertension or angina pectoris or myocardiac infarction
- •History of bowel resection (not including surgery on simple appendicitis)
- •Medication of antipsychotic drugs
- •Herbal medication within 2 months
- •Pregnancy or breastfeeding
- •Participation of other clinical trial(s) within 1 months from screening day
- •Uncooperativeness
- •Intake of dietary supplements within 4 weeks
结局指标
主要结局
Change of serum alanine aminotransferase (ALT)
时间窗: Baseline, 4 weeks and 8 weeks
次要结局
- Change of serum aspartate aminotransferase (AST)(Baseline, 4 weeks and 8 weeks)
- Change of gamma-glutamyl transferase (GGT)(Baseline, 4 weeks and 8 weeks)
- Rate of participants with normalized ALT, AST and GGT(Baseline, 4 weeks and 8 weeks)
- Change of serum bilirubin(Baseline, 4 weeks and 8 weeks)
- Change of multi-dimensional fatigue inventory(Baseline, 4 weeks and 8 weeks)
- Change of serum lipid profiles (triglyceride, total cholesterol, High-density lipoprotein and low-density lipoprotein cholesterol)(Baseline, 4 weeks and 8 weeks)
- Change of antioxidant enzymes (superoxide dismutase, malondialdehyde, glutathione peroxidase)(Baseline, 4 weeks and 8 weeks)
